Decreasing the Adverse Effects of Cancer Therapy: National Cancer Institute Guidance for the Clinical Development of Radiation Injury Mitigators

Benjamin Movsas¹, Bhadrasain Vikram², Martin Hauer-Jensen³, John E. Moulder⁴, Ethan Basch⁵, Stephen L. Brown¹, Lisa A. Kachnic⁶, Adam P. Dicker⁷, C. Norman Coleman², and Paul Okunieff⁸

Abstract

Recently, many agents have been identified that target molecular pathways that can mitigate radiation toxicity. To date, no drugs have been approved as radiation injury mitigators, which are defined as agents administered after irradiation but before toxicity is manifest. In order to accelerate the application of potential mitigators for cancer patients, a meeting sponsored by the National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID) was held in January 2010. This article presents an algorithm to guide clinical trials for such agents in patients receiving radiotherapy or radiochemotherapy. It reviews the mechanisms of radiation injury, the clinical problem, the preclinical and clinical development of candidate agents, and the design and conduct of clinical trials. The central role of patient reported outcomes is outlined, as well as key lessons learned from prior clinical trials. Ultimately, the goal is to be able to apply such promising agents to improve the quality of life for patients receiving radiotherapy or chemoradiotherapy for cancer.

The deleterious effects of radiation exposure, whether administered for treating cancer or malevolent in nature, are well known. However, currently no drugs are approved to mitigate radiation toxicity when given after exposure and only 1 drug, amifostine, has been approved as a radioprotector for administration before or during radiation therapy (1). When vulnerability to terrorist attack became clear after the events of September 11, 2001, the U.S. government funded the Centers for Medical Countermeasures against Radiation (CMCR) under the Project BioShield Act of 2004 to develop agents to be used in the case of a malevolent radiation event. The potential applications of such agents for patients receiving radiation therapy for cancer, however, could have substantial peacetime benefits well beyond their original purpose.

Important in this regard is the recent discovery that many agents (some identified within the CMCR program) target newly identified molecular and physiologic pathways and, thereby, can mitigate radiation toxicity (2–10). The overwhelming majority of putative agents have only been investigated to date for their potential to reduce the toxicity of radiotherapy and not combined modality radiochemotherapy. The term "mitigators" is reserved for agents that are administered after irradiation but before toxicity is manifest (11). It is reasonable to expect that these agents will be less likely to also protect cancer cells than a radiation "protector," which, by definition, is administered before or during radiation. As discussed later, some agents studied have shown no adverse effect on the tumor response and some even seem to enhance tumor response to radiation. However, several logistical, regulatory, and scientific barriers remain that impact the clinical application of these agents in patients with cancer.

In order to better understand those barriers and to accelerate the application of appropriate mitigators in the cancer clinic, a meeting cosponsored by the National Cancer Institute (NCI) and the National Institute of Allergy and Infectious Diseases (NIAID) was held in Rockville, Maryland, on January 25, 2010. More than 50 experts from around the world participated. CMCR and oncology clinical trial group leaders were joined by experts in epidemiology and quality of life issues, representatives from the pharmaceutical industry, patient advocates, and U.S. Food and Drug Administration (FDA) officials. The meeting agenda, participants, abstracts, slides, and video are accessible online. The key objectives were to

1. Recommend best preclinical practices for evaluating agents in the CMCR pipeline for applications in cancer patients

Authors’ Affiliations: ¹Department of Radiation Oncology, Henry Ford Hospital, Detroit, Michigan; ²National Cancer Institute, Rockville, Maryland; ³Division of Radiation Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas; ⁴Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin; ⁵Memorial Sloan-Kettering Cancer Center, New York, New York; ⁶Department of Radiation Oncology, Boston Medical Center, Boston, Massachusetts; ⁷Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania; and ⁸Department of Radiation Oncology, University of Florida Shands Cancer Center, Gainesville, Florida

Corresponding Author: Benjamin Movsas, Radiation Oncology, Henry Ford Hospital, 2799 West Grand Blvd., Detroit, MI 48202. Phone: 313-916-5188; Fax: 313-916-3235; E-mail: bmovsas1@hfhs.org

doi: 10.1158/1078-0432.CCR-10-1402

©2010 American Association for Cancer Research.
Promising agents may be grouped by mechanism of action and timing of administration. Agents with the greatest effect when administered within hours after irradiation (e.g., histone deacetylase inhibitors) probably enhance DNA repair in normal tissues and/or impair DNA repair in tumors (21). Other early mechanisms may include effects on apoptosis and other mediators of cell death (13). Those agents exhibiting their effects when administered days or weeks after irradiation [e.g., angiotensin-converting enzyme (ACE) inhibitors, tetracycline analogs, Cox-2 inhibitors, and statins] may do so by reducing inflammation that would have led to subsequent injury to normal tissues (10, 22–25). As discussed above, decreasing inflammation may enhance anticancer efficacy as well (1, 2, 18). Some of the best-studied agents are those that suppress the renin-angiotensin system via ACE inhibition or angiotensin II receptor blocking. They mitigate radiation nephropathy (2, 6), lung injury (26, 27), and central nervous system injury (28) in experimental animals, as well as clinical radiation nephropathy (29). The efficacy of these agents at clinically relevant drug doses, combined with their widespread clinical use for other indications, makes them attractive for the mitigation of radiation injuries. The third group of agents, perhaps best applied weeks or months after irradiation, includes regenerative agents, such as stem cells (30).

It is important to remember that an agent may produce different effects in different organ systems. For example, inhibition of p53 leads to protection of the bone marrow from radiation but may radiosensitize the gastrointestinal tract (31, 32).

The Clinical Problem

The first step in designing a clinical trial is to define the clinical problem and develop the trial hypothesis (Fig. 1). Grade 3 or worse adverse events are not uncommon during and after radiation therapy (33). They are often accompanied by many other, less serious symptoms that, nonetheless, adversely affect patients’ quality of life. Issues related to the quality, as well as quantity of life, need addressing, and the informed consent process should ensure that patients and their families better understand the effect of treatment on quality of life. Advances in the fields of radiation oncology and medical physics have created sophisticated treatment-planning tools and delivery systems that have helped reduce some of the known toxicities experienced by cancer patients receiving radiotherapy or chemoradiotherapy (34). For example, studies suggest that intensity-modulated radiation therapy and image-guided radiotherapy may reduce the risk of xerostomia in patients with head and neck cancer (35), as well as the risk of radiation pneumonitis in patients with lung cancer (36). Moreover, the definition of normal tissue tolerance has evolved and led to a deeper understanding of the multiparametric inputs that influence toxicity (37). Yet, the impact of such newer radiation technologies and normal tissue constraints has been offset in some cancers by escalation of the radiation dose and concurrent chemotherapy aimed at improving the tumor response.

Evidence is abundant that clinicians underestimate the frequency and severity of patients’ symptoms and,
therefore, the published data underestimate the true toxicity burden (38). In NCI-sponsored trials, for instance, the standard lexicon for reporting adverse events is the Common Terminology Criteria for Adverse Events (CTCAE; ref. 39), an entirely clinician-reported tool, including the 10% of its items that represent symptoms rather than clinical signs and/or observations. To redress this situation, in 2008, the NCI initiated the Patient-Reported Outcomes project (PRO-CTCAE) to create patient versions of those symptoms (40). To date, 77 symptoms of the CTCAE have been converted to PRO-CTCAE items and are currently undergoing...
validation. In a related development, the FDA Guidance document on PROs was recently released in its final form (41), wherein a PRO is defined as any report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the patient’s response by anyone else. Examples include symptoms, quality of life, treatment preferences, satisfaction with care, and medication compliance. PROs have become the gold standard for reporting on these areas, and methodological standards for developing and administering PRO instruments and reporting data collected by such instruments have matured over the past several years. The FDA Guidance encodes these standards and specifies that PRO measures should show reliability, validity, sensitivity to score changes, and have appropriate recall periods. These properties should, therefore, be shown for the population of interest in any given trial.

Preclinical and Clinical Development of Candidate Agents

Guidelines for generating the necessary preclinical data before moving candidate agents into appropriate clinical trials will be published as a separate report. Briefly, agents should be selected on the basis of

1. Protection from or mitigation of radiation injury in at least 1 normal tissue system
2. Lack of tumor protection, or tumor protection that is substantially less than the reduction of damage to the normal tissue(s) of interest; in other words, there is substantial potential for improving the therapeutic ratio.

Many drugs in clinical development fail because of inadequate biological plausibility, inadequately predictive animal models, lack of understanding of the optimal scheduling of the agent, and suboptimal design of the clinical trials. One instructive example is Radiation Therapy Oncology Group (RTOG) study 0315, a 233-patient prospective, placebo-controlled randomized trial of octreotide, a somatostatin analog, for reducing CTCAE grade 2 to 4 acute diarrhea among patients receiving radiation therapy to the pelvis for cancers of the rectum or anus (42). RTOG 0315 found no difference in the incidence of diarrhea between the placebo and octreotide arms. One reason for this result may be that diarrhea in the placebo arm was lower than predicted due to improvements in the technique of irradiation over time. Another factor relates to the use of concurrent chemotherapy in this study. Because octreotide decreases diarrhea related to chemotherapy, this study was not a pure test of the effect of octreotide on radiation bowel injury. Another reason may relate to the underlying mechanism of action of somatostatin in radiation-induced gastrointestinal injury. The contents of the small bowel, most notably the exocrine pancreatic digestive secretions, augment the damage to already compromised small bowel mucosa.

Animal studies showed that surgical removal of the pancreas, pancreatic duct-occlusion, or inhibition of pancreatic enzymes in the bowel lumen reduced deaths after abdominal irradiation (10). Somatostatin analogs inhibit exocrine pancreatic secretions; therefore, this strategy would be most appropriate for protecting the small bowel. Yet, the volume of small bowel irradiated may have been limited in this study that focused on the treatment of anal or rectal cancers. This experience highlights the importance of considering the biological mechanism and the limitations inherent in extrapolating from animals to human studies for cancer patients (6, 9), and suggests how clinical trials in cancer patients can inform the attempts to develop radiation countermeasures for protecting healthy soldiers and civilians.

Phase Zero Trials

The failure rate in clinical trials may also be reduced by applying the principles of phase zero trials during the earliest phases of clinical development. Phase zero trials are “first-in-human” trials designed to evaluate the pharmacodynamic and pharmacokinetic properties of investigational agents in small numbers of patients before initiating larger, traditional trials (43). One type of phase zero trial is designed to evaluate the effect of a drug on its molecular target and/or pathway in humans, using procedures validated in preclinical models. A phase zero trial involves relatively low doses of the drug administered over a short period; therefore, it may be initiated in accordance with the FDA Exploratory IND Guidance15 with less preclinical toxicity data than required for traditional first-in-human studies.

The properties of good drug candidates for phase zero trials include the following:

1. A wide therapeutic window is anticipated (toxicity is not the primary endpoint);
2. Measurable target and/or biomarker modulation is anticipated following treatment with low, nontoxic doses given for 7 days or less (biomarker modification is the primary endpoint);
3. A robust effect is anticipated that can be adequately assessed in a small number of patients using analytical methods validated in preclinical models.

In addition to or instead of formal phase zero trials, these same principles can be employed in more traditional, early-phase trials involving patients with cancer, in order to inform the design of subsequent, larger trials. Such studies in patients with cancer may also add substantial value to radiation countermeasure development, by providing much richer data about the dose ranges of a novel agent, its pharmacokinetics and pharmacodynamics, and, of course, clinical efficacy, than might be ethically justifiable in studies restricted

to healthy volunteers. Phase zero studies in the traditional cancer-drug development pathway typically use normal tissue surrogates (e.g., peripheral blood mononuclear cells) along with tumor for pharmacokinetic and pharmacodynamic evaluation. The use of "normal" tissue is precisely what a mitigator trial will require to ensure that the agent in question is having its desired effect. For example, a hypothetical agent, on the basis of preclinical data, could reduce radiation-induced cytokines by 50%, which might correlate with a 20% reduction in acute toxicity.

**Design and Conduct of Clinical Trials**

Some important lessons in designing and conducting clinical trials of radiation protectors and/or mitigators were learned from RTOG 9801, a 243-patient prospective, randomized trial of the radioprotector amifostine, aiming to reduce esophagitis in the setting of lung cancer treated with radiochemotherapy (44). Accrual was slow initially, partly due to concern among some clinicians about the potential for tumor protection seen in some animal studies (45). Ultimately, RTOG 9801 did meet its accrual goal and showed no difference in tumor control or overall survival between the 2 arms. Concerns about protecting the tumor may be less in the case of mitigators, which are administered after the course of radiation therapy has been completed.

Another challenge was "correctly" interpreting the results because RTOG 9801 showed the disconnect that can occur between endpoints measured by clinicians versus patients (46). According to its primary endpoint (NCI-CTCAE grade of esophagitis, determined by clinicians), the result of RTOG 9801 was null (P = 0.9), yet patients in the amifostine arm, in their daily diaries, reported significantly fewer swallowing problems (P = 0.025), as well as significantly less pain (P = 0.003), using a validated quality of life instrument. Although a placebo effect cannot be excluded, other studies have shown a similar disconnect between physician- and patient-reported outcomes (47, 48). The ongoing PRO-CTCAE project described earlier may, in the future, facilitate better trial design and reduce such discrepancies.

Meeting with the FDA at the pre-IND stage is strongly recommended for addressing concerns about tumor protection, as well as for selecting the most appropriate endpoint(s). A statistical analysis of the degree of tumor protection that may occur can also be done before the IND stage. One strategy is to do a competing risks analysis, considering the severity and frequency of toxicity and balancing that against the impact on survival in the event of unexpected tumor radioprotection. Thus, a quality-adjusted survival analysis can be considered a key goal in designing the study. Early stopping rules based on tumor control endpoints should also be incorporated. In addition, prospective trials in this area will require quality assurance criteria with appropriate imaging studies to objectively evaluate the radiation treatment planning and/or delivery and quantify the volume of normal tissue receiving ionizing radiation.

The RTOG Health Services Research and Outcomes Committee has developed a framework to guide the assessment and testing of an increasingly comprehensive and complex set of outcomes in phase II and III treatment trials (49). This framework has evolved from a triad of clinical, humanistic, and economic endpoints to a model that also includes biological and physical outcomes. The goal is to collect data that will help elucidate the mechanisms of the effects of irradiation on normal tissues and the impact on patients’ experiences. It also acknowledges that there can be significant inter- and intrapatient variability in early and late side effects, reflecting inherent genetic variation (50). Recently, for symptom management trials conducted through the Community Clinical Oncology Program, the RTOG incorporated the framework proposed by the NCI Translational Research Working Group, which conceptualized translational research as a set of 6 developmental pathways focused on various clinical goals (51). The lifestyle alterations pathway (52) may be the most pertinent for symptom reduction and quality of life improvement studies.

In summary, among the priority areas for the oncologic development of promising agents, especially those being developed as radiation countermeasures, are the following:

1. Support for preclinical studies to show lack of protection of tumors;
2. Support for incorporating suitable biomarkers (including imaging agents for normal tissue injury) and patient-reported outcomes into early-phase clinical trials;
3. Support for developing biomarkers, assays, or "signatures" that may help select the most appropriate patients for those trials;
4. Support for the development of "go-no-go" decision criteria and objectives to advance an agent forward.

Funding for such studies may be available, among other sources, from the NIH as research project grants, Small Business Innovation Research grants, and/or Small Business Technology Transfer Research grants.

**Disclosure of Potential Conflicts of Interest**

Dr. Okunieff and his former institution, University of Rochester, along with Eva Pharmaceuticals own intellectual property or licenses for EsA and/ or some fibroblast growth factor analogs identified in this article. No revenue has been generated from these agents to Dr. Okunieff by any of these entities.

**Acknowledgments**

The authors would like to acknowledge David H. Klein, PhD, Julie L. Ryan, MD, George Georges, MD, Nelson J. Chao, MD, and Anthony J. Murgo, MD, for their assistance in the preparation of this article.

Received May 24, 2010; revised September 16, 2010; accepted October 19, 2010; published OnlineFirst November 3, 2010.
References

41. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance


Decreasing the Adverse Effects of Cancer Therapy: National Cancer Institute Guidance for the Clinical Development of Radiation Injury Mitigators

Benjamin Movsas, Bhadrasain Vikram, Martin Hauer-Jensen, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-10-1402

Cited articles
This article cites 47 articles, 10 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/17/2/222.full#ref-list-1

Citing articles
This article has been cited by 4 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/17/2/222.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.